Metronidazole Suppositories
ApprovedSmall molecule
Metronidazole Suppositories is one of 18 small molecule programs targeting Bacterial Vaginosis. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Bacterial Vaginosis
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Mycostatin
GGood Molecules, LLC
Approved
N-Acetyl Cyteien
SStanford University
Approved
Lactobacillus Acidophilus
UUniversiteit Antwerpen
Approved
Tindamax
MMission Pharmacal
Phase 3
Conventional
PPopulation Health Research Institute
Phase 3
Lactoferrin
UUniversità degli Studi di Ferrara
Phase 3
Lactoserum
SanofiApproved
Xifaxan
SSalix
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bacterial Vaginosis2 trials
Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis
Unknown status·—·Phase 4·NCT03446443·240 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metronidazole Suppositories. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details